110 related articles for article (PubMed ID: 11529467)
1. Combination therapy with irinotecan (CPT-11), mitoxantrone, and dexamethasone in relapsed or refractory non-Hodgkin's lymphoma: a pilot study.
Niitsu N; Iijima K; Chizuka A
Ann Hematol; 2001 Jul; 80(7):411-6. PubMed ID: 11529467
[TBL] [Abstract][Full Text] [Related]
2. Combination phase I/II study of irinotecan hydrochloride (CPT-11) and carboplatin in relapsed or refractory non-Hodgkin's lymphoma. CPT-11/Lymphoma Study Group.
Tobinai K; Hotta T; Saito H; Ohnishi K; Ohno R; Ogura M; Ariyoshi Y; Takeyama K; Kobayashi T; Ohashi Y; Shirakawa S
Jpn J Clin Oncol; 1996 Dec; 26(6):455-60. PubMed ID: 9001351
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of the irinotecan (CPT-11), mitoxantrone and dexamethasone regimen in elderly patients with relapsed or refractory peripheral T-cell lymphoma.
Niitsu N; Kohori M; Higashihara M; Bessho M
Cancer Sci; 2007 Jan; 98(1):109-12. PubMed ID: 17052256
[TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin's lymphoma.
Saotome T; Takagi T; Sakai C; Kumagai K; Tamaru J
Ann Oncol; 2000 Jan; 11(1):115-6. PubMed ID: 10690400
[TBL] [Abstract][Full Text] [Related]
5. Irinotecan hydrochloride for the treatment of recurrent and refractory non-Hodgkin lymphoma: a single institution experience.
Sugiyama K; Omachi K; Fujiwara K; Saotome T; Mizunuma N; Takahashi S; Ito Y; Aiba K; Horikoshi N
Cancer; 2002 Feb; 94(3):594-600. PubMed ID: 11857289
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan in relapsed or refractory non-Hodgkin's lymphoma.
Sarris AH; Romaguera J; Hagemeister FB; Rodriguez MA; McLaughlin P; Pro B; Younes A; Mesina O; Cabanillas F; Medeiros LJ; Samuels B
Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):53-6. PubMed ID: 11497233
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of irinotecan (CPT-11) in relapsed or refractory non-Hodgkin's lymphomas.
Ribrag V; Koscielny S; Vantelon JM; Fermé C; Rideller K; Carde P; Bourhis JH; Munck JN
Leuk Lymphoma; 2003 Sep; 44(9):1529-33. PubMed ID: 14565655
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma.
Takagi T; Saotome T
Leuk Lymphoma; 2001 Aug; 42(4):577-86. PubMed ID: 11697485
[TBL] [Abstract][Full Text] [Related]
9. Irinotecan in relapsed or refractory non-Hodgkin's lymphomas. Indications of activity in a phase II trial.
Sarris AH; Phan A; Goy A; Romaguera J; Hagemeister FB; Rodriguez MA; McLaughlin P; Pro B; Medeiros LJ; Samuels B; Mesina O; Bleyer AW; Cabanillas F
Oncology (Williston Park); 2002 Aug; 16(8 Suppl 7):27-31. PubMed ID: 12199630
[TBL] [Abstract][Full Text] [Related]
10. Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma.
Hänel M; Kröger N; Kroschinsky F; Birkmann J; Hänel A; Herbst R; Naumann R; Friedrichsen K; Ehninger G; Zander AR; Fiedler F
J Cancer Res Clin Oncol; 2001; 127(6):387-95. PubMed ID: 11414199
[TBL] [Abstract][Full Text] [Related]
11. Unexpected hepatotoxicities in patients with non-Hodgkin's lymphoma treated with irinotecan (CPT-11) and etoposide.
Ohtsu T; Sasaki Y; Igarashi T; Murayama T; Kobayashi Y; Tobinai K
Jpn J Clin Oncol; 1998 Aug; 28(8):502-6. PubMed ID: 9769785
[TBL] [Abstract][Full Text] [Related]
12. Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
Haq R; Sawka CA; Franssen E; Berinstein NL
Leuk Lymphoma; 1999 Nov; 35(5-6):527-36. PubMed ID: 10609790
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of the combination of irinotecan hydrochloride, carboplatin, and dexamethasone for the treatment of relapsed or refractory malignant lymphoma.
Suzumiya J; Suzushima H; Maeda K; Okamura S; Utsunomiya A; Shibuya T; Tamura K;
Int J Hematol; 2004 Apr; 79(3):266-70. PubMed ID: 15168596
[TBL] [Abstract][Full Text] [Related]
14. A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.
Kakolyris S; Souglakos J; Agelaki S; Kourousis CH; Mavroudis D; Sarra E; Malliotakis P; Georgoulias V
Lung Cancer; 2000 Dec; 30(3):193-8. PubMed ID: 11137204
[TBL] [Abstract][Full Text] [Related]
15. Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer.
Masuda N; Matsui K; Negoro S; Takifuji N; Takeda K; Yana T; Kobayashi M; Hirashima T; Kusunoki Y; Ushijima S; Kawase I; Tada T; Sawaguchi H; Fukuoka M
J Clin Oncol; 1998 Oct; 16(10):3329-34. PubMed ID: 9779709
[TBL] [Abstract][Full Text] [Related]
16. [A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].
Lü SQ; Yang JM; Song XM; Chen L; Zhang WP; Ni X; Xu XQ; Wang JM
Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):710-2. PubMed ID: 18246806
[TBL] [Abstract][Full Text] [Related]
17. [Late phase II clinical study of irinotecan hydrochloride (CPT-11) in the treatment of malignant lymphoma and acute leukemia. The CPT-11 Research Group for Hematological Malignancies].
Ota K; Ohno R; Shirakawa S; Masaoka T; Okada K; Ohashi Y; Taguchi T
Gan To Kagaku Ryoho; 1994 Jun; 21(7):1047-55. PubMed ID: 8210256
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix.
Irvin WP; Price FV; Bailey H; Gelder M; Rosenbluth R; Durivage HJ; Potkul RK
Cancer; 1998 Jan; 82(2):328-33. PubMed ID: 9445190
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of the CPT-11, mitoxantrone and dexamethasone regimen in combination with rituximab in elderly patients with relapsed diffuse large B-cell lymphoma.
Niitsu N; Kohuri M; Higashihara M; Bessho M
Cancer Sci; 2006 Sep; 97(9):933-7. PubMed ID: 16805825
[TBL] [Abstract][Full Text] [Related]
20. Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone).
Zwick C; Birkmann J; Peter N; Bodenstein H; Fuchs R; Hänel M; Reiser M; Hensel M; Clemens M; Zeynalova S; Ziepert M; Pfreundschuh M;
Ann Hematol; 2008 Sep; 87(9):717-26. PubMed ID: 18587579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
